Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1325 of 2051 entries
View as:

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Phase: N/A Priority: Normal
NCT ID: NCT01716234 Org: User:
Start: 04/17/08 End: 04/01/15 Due: 04/01/16

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT03850444 Org: User:
Start: 08/01/16 End: 09/08/22 Due: 09/08/23

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00090207 Org: User:
Start: 01/13/04 End: 09/30/04 Due: 09/30/05

A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)

Phase: N/A Priority: Normal
NCT ID: NCT00550732 Org: User:
Start: 12/31/07 End: 11/30/12 Due: 11/30/13

A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)

Phase: N/A Priority: Normal
NCT ID: NCT00543413 Org: User:
Start: 10/31/07 End: 06/30/08 Due: 06/30/09

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00565292 Org: User:
Start: 07/31/06 End: 08/31/06 Due: 08/31/07

Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

Phase: N/A Priority: Normal
NCT ID: NCT01391546 Org: User:
Start: 06/20/11 End: 10/15/12 Due: 10/15/13

A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)

Phase: N/A Priority: Normal
NCT ID: NCT00090272 Org: User:
Start: 04/30/02 End: 03/31/05 Due: 03/31/06

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Phase: N/A Priority: Normal
NCT ID: NCT03909165 Org: User:
Start: 07/23/19 End: 09/21/23 Due: 09/21/24

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Phase: N/A Priority: Normal
NCT ID: NCT03176134 Org: User:
Start: 01/20/19 End: 07/06/23 Due: 07/06/24

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00250419 Org: User:
Start: 09/30/05 End: 09/30/08 Due: 09/30/09

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Phase: N/A Priority: Normal
NCT ID: NCT01974687 Org: User:
Start: 10/31/13 End: 09/11/15 Due: 09/11/16

Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)

Phase: N/A Priority: Normal
NCT ID: NCT00367237 Org: User:
Start: 05/31/06 End: 03/31/08 Due: 03/31/09

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Phase: N/A Priority: Normal
NCT ID: NCT04939428 Org: User:
Start: 08/11/21 End: 11/16/22 Due: 11/16/23

Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)

Phase: N/A Priority: Normal
NCT ID: NCT01293656 Org: User:
Start: 08/31/11 End: 07/31/12 Due: 07/31/13

Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Phase: N/A Priority: Normal
NCT ID: NCT01125774 Org: User:
Start: 06/01/10 End: 04/08/11 Due: 04/08/12

Dose Confirmation Efficacy Study (V260-007)

Phase: N/A Priority: Normal
NCT ID: NCT00092443 Org: User:
Start: 09/30/02 End: 06/30/04 Due: 06/30/05

Endpoint Validation Study (0524A-015)

Phase: N/A Priority: Normal
NCT ID: NCT00533676 Org: User:
Start: 08/31/04 End: 12/31/06 Due: 12/31/07

A Multiple Dose Study of MK-3614 (MK-3614-002)

Phase: N/A Priority: Normal
NCT ID: NCT01033643 Org: User:
Start: 05/27/09 End: 12/09/09 Due: 12/09/10

A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Phase: N/A Priority: Normal
NCT ID: NCT00885170 Org: User:
Start: 04/13/09 End: 09/15/11 Due: 09/15/12

Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00686686 Org: User:
Start: 12/31/07 End: 04/30/09 Due: 04/30/10

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Phase: N/A Priority: Normal
NCT ID: NCT00730275 Org: User:
Start: 07/18/08 End: 02/14/11 Due: 02/14/12

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Phase: N/A Priority: Normal
NCT ID: NCT00961480 Org: User:
Start: 10/31/07 End: 11/30/07 Due: 11/30/08

A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00953056 Org: User:
Start: 09/30/09 End: 03/31/10 Due: 03/31/11

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Phase: N/A Priority: Normal
NCT ID: NCT02447003 Org: User:
Start: 06/11/15 End: 01/31/20 Due: 01/31/21